Clinical effectiveness and versatility of a sealing hemostatic patch (HEMOPATCH) in multiple surgical specialties
- 16 April 2018
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Medical Devices
- Vol. 15 (5), 367-376
- https://doi.org/10.1080/17434440.2018.1464909
Abstract
Introduction: Intraoperative surgical sealants and hemostatic agents have been shown to reduce postoperative complications, transfusions, and hospital resource utilization. Despite availability of these agents, the incidence and burden of bleeding remains high and surgeons' requirements for hemostatic control continue to evolve. A burgeoning class of hemostatic agents are hemostatic patches, which offer package-to-patient readiness and direct application. In addition, hemostatic patches may provide tissue sealing capabilities.Areas covered: This review focuses on the clinical effectiveness, versatility, and surgical efficiency of HEMOPATCH as a surgical sealant and hemostatic agent in various surgical specialties including: cardiac, digestive (hepatic, gastrointestinal, pancreatic), urological, neurological, and endocrine.Expert commentary: Among hemostatic patches, HEMOPATCH is a valuable tool to stop bleeding without adverse events across various surgical specialties. Clinical evidence demonstrates the safety, clinical effectiveness, and versatility of HEMOPATCH as a unique surgical adjunct in patients undergoing complex and routine surgical procedures. Larger randomized-controlled clinical studies, or clinical registries, will continue to be used to evaluate its performance and versatility, particularly for sealing tissues and closing the dura. In the current field of surgical sealing and hemostasis, however, HEMOPATCH represents the next step in improving patient outcomes.Funding Information
- Baxter Healthcare Corporation
This publication has 56 references indexed in Scilit:
- A Prospective, Randomized, Controlled Trial of the Efficacy and Safety of Fibrin Pad as an Adjunct to Control Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic SurgeryJournal of the American College of Surgeons, 2013
- Fibrin Sealant (Evicel® [Quixil®/Crosseal™])Drugs, 2011
- The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleedingEuropean Journal of Cardio-Thoracic Surgery, 2011
- Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patientsBMC Health Services Research, 2011
- The incidence, root-causes, and outcomes of adverse events in surgical units: implication for potential prevention strategiesPatient Safety in Surgery, 2011
- A comparison of the mechanical, kinetic, and biochemical properties of fibrin clots formed with two different fibrin sealantsBlood Coagulation & Fibrinolysis, 2011
- A Surgical Safety Checklist to Reduce Morbidity and Mortality in a Global PopulationThe New England Journal of Medicine, 2009
- Topical Hemostatic Agents in Surgery: A Surgeon's PerspectiveAORN Journal, 2008
- Indications for Blood Transfusion in Cardiac SurgeryThe Annals of Thoracic Surgery, 2006
- Controlled clinical trial of a novel hemostatic agent in cardiac surgeryThe Annals of Thoracic Surgery, 2000